Share price · BIIB
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when BIIB's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 28 Oct 2026-3.4%
- 22 Oct 2026+5.3%
- Stoke Therapeutics, Inc.: Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial UpdatesSTOK +0.1%
- 14 Jul 2026-8.2%
- 13 Jul 2026+5.0%
- 14 May 2026-6.4%
- 29 Apr 2026+6.0%
- 20 Apr 2026+3.4%
Nothing announced by BIIB that day or the session before.
- 6 Feb 2026+8.5%
- 4 Feb 2026+4.9%
Nothing announced by BIIB that day or the session before.
- 14 Jan 2026-5.0%
Share of unusual movement by asset
For each asset, the share of BIIB's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(20 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | Nrf2 pathway (fumaric acid ester)Small molecule | Multiple Sclerosis | |
Diroximel fumarate(Vumerity) | Approved | Nrf2 pathway (fumaric acid ester)Small molecule | Multiple Sclerosis |
| Approved | Type I Interferon receptor (IFNAR)Biologic (subtype unspecified) | Multiple Sclerosis | |
Lecanemab(Leqembi) | Approved | Amyloid-beta (monoclonal antibody)Monoclonal antibody | Alzheimer's Disease |
natalizumab(Tysabri) | Approved | α4 integrinMonoclonal antibody | Inflammatory Bowel DiseaseMultiple Sclerosis Crohn's Disease |
Nusinersen(Spinraza) | Approved | SMN2 pre-mRNARNA / oligonucleotide | Spinal Muscular Atrophy |
Pegcetacoplan(Empaveli) | Approved | Complement C3Peptide | Complement-Mediated Renal DiseaseParoxysmal Nocturnal Hemoglobinuria |
Pegcetacoplan ophthalmic(Syfovre) | Approved | Complement C3 · Complement C3 / C3bPeptide | Age-Related Macular Degeneration |
peginterferon beta-1a(Plegridy) | Approved | Type I interferon receptor · Interferon beta receptor (type I IFN signaling)Biologic (subtype unspecified) | Multiple Sclerosis |
Rituximab(Rituxan) | Approved | CD20 · CD20-directed Cytolytic AntibodyMonoclonal antibody | Rheumatoid ArthritisDiffuse Large B-Cell LymphomaFollicular LymphomaChronic Lymphocytic Leukemia |
Tofersen(Qalsody) | Approved | SOD1RNA / oligonucleotide | Amyotrophic Lateral Sclerosis |
| Phase 3 | LRRK2Small molecule | Parkinson's Disease | |
| Phase 3 | CD38Monoclonal antibody | Multiple MyelomaIgA NephropathyPrimary Membranous Nephropathy | |
| Phase 3 | BDCA2 (CLEC4C) · BDCA2 / CD303 (blood dendritic cell antigen 2)Monoclonal antibody | Systemic Lupus Erythematosus | |
| Phase 3 | SCN1A mRNARNA / oligonucleotide | Dravet Syndrome |
Discontinued programmes (2)
Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events
(27 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (4)
December 2026 (4)
2027 (9)
March 2027 (2)
May 2027 (2)
July 2027 (2)
What to watch
What to watch
August 2027 (1)
What to watch
September 2027 (1)
What to watch
October 2027 (1)
What to watch
2028 (6)
January 2028 (1)
What to watch
February 2028 (1)
What to watch
August 2028 (1)
What to watch
September 2028 (1)
What to watch
2029 (3)
2030 (1)
January 2030 (1)
What to watch
2031 (2)
January 2031 (1)
What to watch
December 2031 (1)
What to watch
2032 (1)
May 2032 (1)
What to watch
2034 (1)
July 2034 (1)
What to watch
Regulatory and conference events
(20)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
The 12 most recent of 20 past events are shown.
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $2.8B | $574M | $1.3B+ $0 short-term inv. | $21M$641M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $2.7B | $530M | $1.3B+ $0 short-term inv. | —$449M operating cash flow | report ↗ |
| 2026-Q1 | $2.5B | $539M | $3.4B+ $900M short-term inv. | —$646M operating cash flow | report ↗ |
| 2025-Q3 | $2.5B | $436M | $3.9B+ $98M short-term inv. | —$1.3B operating cash flow | report ↗ |
| 2025-Q2 | $2.6B | $399M | $2.8B | —$161M operating cash flow | report ↗ |
| 2025-Q1 | $2.4B | $434M | $2.6B | —$259M operating cash flow | report ↗ |
| 2024-Q3 | $2.5B | $543M | $1.7B | —$936M operating cash flow | report ↗ |
| 2024-Q2 | $2.5B | $514M | $1.9B | —$626M operating cash flow | report ↗ |
| 2024-Q1 | $2.3B | $453M | $1.1B | —$553M operating cash flow | report ↗ |
| 2023-Q3 | $2.5B | $736M | $2.3B+ $0 short-term inv. | $68M$592M operating cash flow | report ↗ |
| 2023-Q2 | $2.5B | $584M | $2.6B+ $3.5B short-term inv. | —$487M operating cash flow | report ↗ |
| 2023-Q1 | $2.5B | $571M | $2.9B+ $2.1B short-term inv. | —$455M operating cash flow | report ↗ |
| 2022-Q3 | $2.5B | $549M | $3.7B+ $1.2B short-term inv. | —$661M operating cash flow | report ↗ |
| 2022-Q2 | $2.6B | $529M | $2.6B+ $2.2B short-term inv. | —$737M operating cash flow | report ↗ |
| 2022-Q1 | $2.5B | $552M | $1.7B+ $2.0B short-term inv. | —$162M operating cash flow | report ↗ |
| 2021-Q3 | $2.8B | $702M | $1.5B+ $1.4B short-term inv. | —$805M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $9.9B | $1.8B | $3.0B+ $807M short-term inv. | —$2.2B operating cash flow | report ↗ |
Biogen reported full-year 2025 revenue of $9,890.6M, up 2.2% YoY, with R&D spend of $1,778.6M, down 12.9% YoY. Cash and equivalents were $3,008.5M, and net income attributable to Biogen was $1,292.9M. Reported GAAP diluted EPS was $8.79, while non-GAAP diluted EPS was $15.28, exceeding the company’s full-year 2025 non-GAAP guidance range of $14.50 to $15.00.
For 2026, Biogen guided non-GAAP diluted EPS of $15.25 to $16.25 and expects total revenue to decline by a mid-single digit percentage versus 2025. Key pipeline and regulatory events include FDA Priority Review for LEQEMBI IQLIK subcutaneous treatment initiation with a PDUFA date of May 24, 2026, Breakthrough Therapy Designation for litifilimab in cutaneous lupus, expected Phase 3 systemic lupus readouts in Q4 2026, high-dose SPINRAZA approvals in Japan and the E.U. with a U.S. PDUFA of April 3, 2026, and initiation of a Phase 1 study for the BTK degrader BIIB145 in autoimmune diseases.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $9.7B | $2.0B | $2.4B+ $0 short-term inv. | —$2.9B operating cash flow | report ↗ |
| 2023-FY | $9.8B | $2.5B | $1.0B+ $0 short-term inv. | —$1.5B operating cash flow | report ↗ |
| 2022-FY | $10.2B | $2.2B | $3.4B+ $1.5B short-term inv. | —$1.4B operating cash flow | report ↗ |
| 2021-FY | $11.0B | $2.5B | $2.3B+ $1.5B short-term inv. | —$3.6B operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 1 purchase ($585), 4 sales ($905K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-30 | Grogan Jane · Head of Research | Option exercise | 695 | — | — | Form 4 |
| 2026-10-30 | Grogan Jane · Head of Research | Tax withholding | 345 | $253.62 | $87K | Form 4 |
| 2026-10-30 | Grogan Jane · Head of Research | Option exercise (derivative) | 695 | — | — | Form 4 |
| 2026-10-02 | Godbout Sean · Chief Accounting Officer | Option exercise | 27 | — | — | Form 4 |
| 2026-10-02 | Godbout Sean · Chief Accounting Officer | Tax withholding | 8 | $219.88 | $2K | Form 4 |
| 2026-10-02 | Godbout Sean · Chief Accounting Officer | Option exercise (derivative) | 27 | — | — | Form 4 |
| 2026-10-01 | Godbout Sean · Chief Accounting Officer | Award / grant (derivative) | 985 | — | — | Form 4 |
| 2026-09-01 | Parini Michael · Chief Legal Officer | Award / grant (derivative) | 7,405 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 990 reporting institutions held 134.2M shares ($23.7B, 90.8% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 15,974,601 | $2.9B |
| 2 | PRIMECAP MANAGEMENT CO/CA/ | 14,757,607 | $2.7B |
| 3 | FMR LLC | 12,807,541 | $2.3B |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 9,537,417 | $1.7B |
| 5 | STATE STREET CORP | 7,167,922 | $1.3B |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | 6,531,727 | $1.2B |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 4,342,602 | $793.4M |
| 8 | WELLINGTON MANAGEMENT GROUP LLP | 2,961,641 | $543.0M |
| 9 | MORGAN STANLEY | 2,170,940 | $398.0M |
| 10 | JPMORGAN CHASE & CO | 2,016,009 | $378.1M |
| 11 | AQR CAPITAL MANAGEMENT LLC | 1,923,557 | $346.2M |
| 12 | Invesco Ltd. | 1,745,255 | $320.0M |
| 13 | Boston Partners | 1,700,078 | $311.7M |
| 14 | NORTHERN TRUST CORP | 1,446,579 | $265.2M |
| 15 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1,377,568 | $252.5M |